SEARCH

SEARCH BY CITATION

References

  • 1
    Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000;47:21545.
  • 2
    Shaw LM, Holt DW, Oellerich M, Meiser B, Van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001;23:30515.
  • 3
    Van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:14554.
  • 4
    Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:67283.
  • 5
    Weber LT, Shipkova M, Armstrong VW, Wagner N, Schütz E, Mehls O et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002;13:75968.
  • 6
    Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003;25:13757.
  • 7
    Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:1358.
  • 8
    Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000;38:121316.
  • 9
    Budde K, Braun KP, Glander P, Böhler T, Hambach P, Fritsche L et al. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. Transplant Proc 2002;34:174850.
  • 10
    Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest 2006;66:3144.
  • 11
    Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004;4:204551.
  • 12
    Millan O, Oppenheimer F, Brunet M, Vilardell J, Rojo I, Vives J et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000;46:137683.
  • 13
    Digits JA, Hedstrom L. Species-specific inhibition of inosine 5′-monophosphate dehydrogenase by mycophenolic acid. Biochemistry 1999;38:1538897.
  • 14
    Futer O, Sintchak MD, Caron PR, Nimmesgern E, DeCenzo MT, Livingston DJ et al. A mutational analysis of the active site of human type II inosine 5′-monophosphate dehydrogenase. Biochim Biophys Acta 2002;1594:2739.
  • 15
    McPhillips CC, Hyle JW, Reines D. Detection of the mycophenolate-inhibited form of IMP dehydrogenase in vivo. Proc Natl Acad Sci USA 2004;101:121716.
  • 16
    Roberts RL, Gearry RB, Barclay ML, Kennedy MA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 2007;7:3127.
  • 17
    Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008;83:71117.
  • 18
    Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA et al. Banff schema for grading pancreas allograft rejection: working proposal by a multi-disciplinary international consensus panel. Am J Transplant 2008;8:123749.
  • 19
    Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H et al. Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. Yakugaku Zasshi 2006;126:135762.
  • 20
    Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K et al. Circadian pharmacokinetics of mycophenolic acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 2006;82:48693.
  • 21
    Kagaya H, Inoue K, Miura M, Satoh S, Saito M, Tada H et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007;63:27988.
  • 22
    Van Gelder T, Silva HT, De Fijter JW, Budde K, Kuypers D, Tyden G et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008;86:104351.
  • 23
    Kiberd BA, Lawen J, Fraser AD, Keough-Ryan T, Belitsky P. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004;4:107983.
  • 24
    Sombogaard F, Van Schaik RH, Mathot RA, Budde K, Van Der Werf M, Vulto AG et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics 2009;19:62634.
  • 25
    Van Schaik RH, Van Agteren M, De Fijter JW, Hartmann A, Schmidt J, Budde K et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009;86:31927.
  • 26
    Kuypers DR, Naesens M, Vermeire S, Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 2005;78:35161.
  • 27
    Saeki M, Saito Y, Jinno H, Sai K, Ozawa S, Kurose K et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J 2006;6:6375.
  • 28
    Inoue K, Miura M, Satoh S, Kagaya H, Saito M, Habuchi T et al. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Ther Drug Monit 2007;29:299304.